Parkman Healthcare Partners LLC Raises Stake in Qiagen N.V. $QGEN

Key Points

• Parkman Healthcare Partners LLC increased its stake in Qiagen N.V. by 29.7% by acquiring an additional 82,372 shares, bringing its total ownership to 359,644 shares.
• Wall Street analysts have mixed views on Qiagen, with consensus ratings showing three "Buy" ratings and eight "Hold" ratings, while the price target averages around $49.69.
• Qiagen's recent earnings report showed a revenue of $533.54 million and an EPS of $0.60, indicating a 7.7% year-over-year revenue growth.

Parkman Healthcare Partners LLC boosted its stake in Qiagen N.V. (NYSE:QGEN - Free Report) by 29.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 359,644 shares of the company's stock after purchasing an additional 82,372 shares during the period. Qiagen comprises approximately 1.7% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 23rd biggest position. Parkman Healthcare Partners LLC owned approximately 0.16% of Qiagen worth $14,440,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in shares of Qiagen by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after acquiring an additional 2,204 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Qiagen by 3.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 96,482 shares of the company's stock valued at $4,322,000 after buying an additional 2,832 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Qiagen by 40.9% in the 4th quarter. AQR Capital Management LLC now owns 105,303 shares of the company's stock worth $4,689,000 after acquiring an additional 30,571 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Qiagen by 66.3% during the fourth quarter. Ameriprise Financial Inc. now owns 63,026 shares of the company's stock worth $2,807,000 after purchasing an additional 25,134 shares during the last quarter. Finally, Cetera Investment Advisers grew its position in Qiagen by 14.4% in the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock worth $505,000 after purchasing an additional 1,418 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Qiagen Price Performance

Shares of NYSE:QGEN traded up $0.05 during trading on Thursday, reaching $46.06. The company had a trading volume of 1,174,056 shares, compared to its average volume of 1,384,047. The company has a fifty day moving average of $48.57 and a two-hundred day moving average of $44.51. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $10.24 billion, a P/E ratio of 27.21, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64. Qiagen N.V. has a 12 month low of $37.63 and a 12 month high of $51.88.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts' consensus estimates of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same quarter in the previous year, the company posted $0.55 EPS. Qiagen's quarterly revenue was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities research analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on QGEN shares. Bank of America raised their price objective on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Cowen restated a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. UBS Group upped their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Barclays initiated coverage on shares of Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price for the company. Finally, Wall Street Zen lowered shares of Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.